| Primary | Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score at Baseline. | The PANSS is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening. | The Intent-to-Treat population included all randomly assigned subjects who received at least 1 dose of study medication (or any portion of a dose) and had both baseline and at least 1 postbaseline PANSS assessment. | Posted | | Mean | Standard Deviation | points on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00091.7± 12.1
- OG00192.3± 13.5
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | ANOVA | P-value based on the actual value and was from an ANOVA model with fixed effects for treatment, concomitant medication stratum, and country. | 0.774 | | LS Mean Difference | 0.5 | Standard Error of the Mean | 1.6 | | 95 | -2.7 | 3.7 | | | Paliperidone Extended Release (ER) - Placebo on the Actual Score. | No | Superiority or Other | | |
|
| Primary | Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | The PANSS is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening. | The Intent-to-Treat population included all randomly assigned subjects who received at least 1 dose of study medication (or any portion of a dose) and had both baseline and at least 1 postbaseline PANSS assessment. | Posted | Jun 2009 | Mean | Standard Deviation | points on a scale | | The primary efficacy endpoint was the change from baseline to week 6 or the last post-randomization assessment during double-blind treatment in the PANSS total score. | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) Positive Subscale Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) Negative Subscale Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) General Psychopathology Subscale Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) Positive Factor Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Positive PANSS Factor Score (range 8-56): Sum of scores for items 1, 3, 5, and 6 in positive subscale: delusions, hallucinatory behavior, grandiosity, suspiciousness; item 7 in negative subscale: stereotyped thinking; and items 1, 9, and 12 in general psychopathology subscale: somatic concern, unusual thought content, lack of judgment, and insight. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) Negative Factor Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Negative PANSS Factor Score (range 7-49): Sum of scores for items 1, 2, 3, 4, and 6 in negative subscale: blunted affect, emotional withdrawal, poor rapport, passive social withdrawal, lack of spontaneity; and items 7 and 16 in general psychopathology subscale: motor retardation, and active social avoidance. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) Disorganized Thought Factor Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Disorganized Thoughts PANSS Factor Score (range 7-49): Sum of scores for item 2 in positive subscale:Conceptual disorganization; item 5 in negative subscale:difficulty in abstract thinking; and items 5, 10, 11, 13, and 15 in general psychopathology subscale: mannerisms/posturing, disorientation, poor attention, disturbance of volition, and preoccupation. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) Uncontrolled Hostility/Excitement Factor Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Uncontrolled Hostility/Excitement PANSS Factor Score (range 4-28): Sum of scores for items 4 and 7 in positive subscale: excitement, hostility; and items 8 and 14 in general psychopathology subscale: uncooperativeness, and poor impulse control. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Secondary | Positive and Negative Symptoms of Schizophrenia (PANSS) Anxiety/Depression Factor Score - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Anxiety/Depression PANSS Factor Score (range 4-28): Sum of scores for items 2, 3, 4, and 6 in general psychopathology subscale: Anxiety, Guilt feelings, Tension, Depression. Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Secondary | Clinical Global Impression (CGI-S) - Severity for Schizoaffective Disorder Score at Baseline | The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a subject. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill subjects". Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Secondary | Clinical Global Impression (CGI-S) - Severity for Schizoaffective Disorder - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a subject. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill subjects". Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Secondary | Clinical Global Impression (CGI-C) - Change for Schizoaffective Disorder | The CGI-C rating scale is a 7 point global assessment that measures the clinician's impression of the change occurring in the illness over a course of treatment, relative to baseline. A rating of 4 is equivalent to "No change". Ratings of <4 are equivalent to "improvement" and ratings of > 4 are equivalent to "worsening". Higher scores indicate worsening. | | Posted | | Mean | Standard Deviation | points on a scale | | Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Secondary | Participants With Response | Response is defined as a 30% or more reduction from baseline PANSS total score and CGI-C score of <= 2 (CGI-C-SCA: Clinical Global Impression of Change for Schizoaffective Disorder). | | Posted | | Number | | participants | | Week 6 LOCF End Point | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Other Pre-specified | Baseline Hamilton Rating Scale for Depression (HAM-D-21) With Baseline HAM-D-21 Total Score >= 16 | Clinician-rated scale that evaluates depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on either a 5-point (0 to 4) or a 3-point (0 to 2) scale. The 5-point scale uses a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). Higher scores indicate worsening. The responses are summed to yield the HAM-D-21 score that ranges from 0-63. | | Posted | | Mean | Standard Deviation | points on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Other Pre-specified | Hamilton Rating Scale for Depression (HAM-D-21) With Baseline HAM-D-21 Total Score >= 16 - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | Clinician-rated scale that evaluates depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on either a 5-point (0 to 4) or a 3-point (0 to 2) scale. The 5-point scale uses a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). Higher scores indicate worsening. The responses are summed to yield the HAM-D-21 score that ranges from 0-63. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|
| Other Pre-specified | Baseline Young Mania Rating Scale (YMRS) With Baseline YMRS Total Score >= 16 | 11-item scale (elevated mood, increased motor activity, sexual interest, sleep, irritability, speech [rate/amount], language-thought disorder, content, disruptive-aggressive behaviors, appearance, and insight) based on subject's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. The responses are summed to yield the YMRS total score, which ranges from 0 to 60. | | Posted | | Mean | Standard Deviation | points on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
| |
| Other Pre-specified | Young Mania Rating Scale (YMRS) With Baseline YMRS Total Score >= 16 - Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) End Point. | 11-item scale (elevated mood, increased motor activity, sexual interest, sleep, irritability, speech [rate/amount], language-thought disorder, content, disruptive-aggressive behaviors, appearance, and insight) based on subject's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. The responses are summed to yield the YMRS total score, which ranges from 0 to 60. | | Posted | | Mean | Standard Deviation | points on a scale | | Change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment | | | | ID | Title | Description |
|---|
| OG000 | Placebo | A placebo control was used to establish the frequency and magnitude of changes in clinical endpoints that could occur in the absence of active treatment. | | OG001 | Paliperidone Extended-Release (ER) | Paliperidone (9-hydroxy-risperidone, R076477) is an atypical antipsychotic agent approved for the treatment of schizophrenia and is in development for the treatment of bipolar disorder and schizoaffective disorder. Paliperidone is a monoaminergic antagonist that exhibits the characteristic dopamine type 2 (D2) and serotonin (5-hydroxytryptamine [5-HT]) type 2A (5HT2A) antagonism of the newer, or second-generation, antipsychotic drugs. Paliperidone is available in an oral formulation using extended-release (ER). |
|